Nang Kuang Pharmaceutical Co., Ltd. (TPE:1752)
Taiwan · Delayed Price · Currency is TWD 31.50
-0.25 (-0.79%)
Sep 8, 2026, 1:30 PM CST
Nang Kuang Pharmaceutical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,181 | 3,767 | 4,156 | 5,383 | 6,453 | 3,888 | |
Market Cap Growth | -18.08% | -9.36% | -22.80% | -16.59% | 65.97% | -2.78% |
Enterprise Value | 3,506 | 4,208 | 4,435 | 5,681 | 6,651 | 4,113 |
Last Close Price | 31.50 | 35.50 | 37.45 | 46.71 | 53.99 | 30.95 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 15.51 | 15.41 | 17.07 | 27.13 | 18.33 | 19.83 |
Forward PE | - | 14.92 | 17.95 | 19.68 | 21.30 | 14.55 |
PS Ratio | 1.51 | 1.74 | 1.89 | 2.50 | 3.33 | 2.18 |
PB Ratio | 1.32 | 1.51 | 1.72 | 2.26 | 2.68 | 1.74 |
P/TBV Ratio | 1.33 | 1.52 | 1.72 | 2.27 | 2.68 | 1.74 |
P/FCF Ratio | 21.99 | 20.22 | - | 119.36 | 23.44 | 9.71 |
P/OCF Ratio | 9.06 | 8.12 | 8.91 | 15.71 | 17.48 | 6.99 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.66 | 1.95 | 2.02 | 2.64 | 3.43 | 2.31 |
EV/EBITDA Ratio | 7.94 | 8.80 | 9.01 | 12.89 | 13.39 | 9.49 |
EV/EBIT Ratio | 13.42 | 14.23 | 14.30 | 21.86 | 20.68 | 16.16 |
EV/FCF Ratio | 24.24 | 22.59 | - | 125.98 | 24.16 | 10.27 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.28 | 0.26 | 0.26 | 0.30 | 0.17 | 0.24 |
Debt / EBITDA Ratio | 1.55 | 1.37 | 1.29 | 1.60 | 0.82 | 1.23 |
Debt / FCF Ratio | 4.73 | 3.52 | - | 15.65 | 1.49 | 1.33 |
Net Debt / Equity Ratio | 0.13 | 0.13 | 0.14 | 0.14 | 0.00 | 0.05 |
Net Debt / EBITDA Ratio | 0.73 | 0.65 | 0.68 | 0.74 | 0.01 | 0.26 |
Net Debt / FCF Ratio | 2.22 | 1.67 | -5.79 | 7.25 | 0.02 | 0.29 |
Asset Turnover | 0.54 | 0.57 | 0.57 | 0.58 | 0.55 | 0.53 |
Inventory Turnover | 1.83 | 1.93 | 1.97 | 1.75 | 1.63 | 1.61 |
Quick Ratio | 0.67 | 0.67 | 0.63 | 0.59 | 0.76 | 0.72 |
Current Ratio | 1.41 | 1.40 | 1.27 | 1.20 | 1.58 | 1.39 |
Return on Equity (ROE) | 8.50% | 9.93% | 10.14% | 8.29% | 15.14% | 8.82% |
Return on Assets (ROA) | 4.21% | 4.84% | 5.06% | 4.37% | 5.73% | 4.75% |
Return on Invested Capital (ROIC) | 8.03% | 8.91% | 9.12% | 9.42% | 11.56% | 8.91% |
Return on Capital Employed (ROCE) | 9.30% | 10.70% | 11.60% | 10.10% | 12.60% | 10.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.46% | 6.49% | 5.86% | 3.69% | 5.46% | 5.04% |
FCF Yield | 4.55% | 4.95% | -1.40% | 0.84% | 4.27% | 10.30% |
Dividend Yield | 5.09% | - | 4.27% | 4.28% | 4.26% | 5.82% |
Payout Ratio | 78.67% | 66.11% | 82.98% | 117.07% | 51.64% | 82.39% |
Buyback Yield / Dilution | 0.12% | -0.02% | -0.10% | 0.08% | 0.01% | -0.03% |
Total Shareholder Return | 5.21% | -0.02% | 4.17% | 4.36% | 4.27% | 5.78% |